drugset / Trial / NCT07138378

A Bioavailability Study of Nilotinib in Healthy, Adult, Human Subjects Under Fasted Conditions.

NCT07138378

Phase 1 Completed 128 enrolled Xspray Pharma AB
RandomizedCrossoverOpen-labelTreatment

Summary

An open label, single-center, balanced, randomized, four-treatment, four-sequence, four-period, single dose, crossover, comparative bioavailability study in healthy, adult, human subjects under fasteding conditions

Timeline

Start
2024-11-15
Primary completion
2024-12-15
Completion
2024-12-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Nilotinib Small molecule 96 mg
Subject Nilotinib Small molecule 192 mg
Subject Nilotinib Small molecule 200 mg
Subject Nilotinib Small molecule 400 mg

Indications